Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab
April 17, 2018
- Generic Drug Makers Required to Improve Package Inserts by Adding Information from Clinical Studies: MHLW Notification
April 17, 2018
- Xeljanz’s Ulcerative Colitis Use Up for MHLW Panel Review on April 27
April 16, 2018
- MHLW to Draft GL on Detailing Activities by Drug Reps as Early as Summer
April 13, 2018
- MHLW Compiles Drug Reuse Guide to Reduce Leftover Drug Solutions
April 13, 2018
- AZ’s PD-L1 Inhibitor Durvalumab Up for MHLW Panel Review on April 25
April 13, 2018
- MHLW to Issue Optimal Use Guidelines for Dupixent, Tecentriq
April 12, 2018
- MHLW Panel Starts Discussions on PMD Law Amendment; Will First Verify Results of Previous Amendment
April 12, 2018
- Chuikyo Holds 1st Listing Discussions since Overhaul, US Reference Prices Show Marked Declines after Rule Change
April 12, 2018
- Chuikyo Payer Rep Questions New Premium System for Cost-Based Pricing Method
April 12, 2018
- MOF Calls for Using CEA to Make Reimbursement Decisions for Pricy Drugs
April 12, 2018
- Pricing OK’ed for Dupixent, Tecentriq, Lynparza, and More; Parmodia Skips Listing Yet Again
April 11, 2018
- Doctor Calls for Incentives for Effective, Lower-Cost Existing Drugs: LDP Taskforce
April 10, 2018
- MHLW Inks Memorandum of Cooperation with FDA Thailand
April 10, 2018
- MHLW to Launch New Public-Private Confab Focusing on Drug Pricing
April 10, 2018
- Mandatory Generic Use Tantamount to Treating Welfare Recipients in “Inferior” Manner: Lawmaker
April 6, 2018
- MEXT to Support Establishment of “Open Innovation Organizations” at Universities
April 6, 2018
- Invest in DNA-Based Prevention for Cancer, Dementia and Other Technological Innovation: CEFP Member
April 5, 2018
- MHLW Panel to Kick Off Debates on Amendment of Pharmaceuticals and Medical Devices Law
April 5, 2018
- PMDA Announces Report Outlining “Current Views” on Introduction of Continuous Manufacturing
April 5, 2018
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…